Candel Therapeutics Inc (NASDAQ:CADL) price on Thursday, December 26, rose 4.20% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $9.17.
A look at the stock’s price movement, the close in the last trading session was $8.80, moving within a range at $8.62 and $9.27. The beta value (5-Year monthly) was -0.874. Turning to its 52-week performance, $14.60 and $1.10 were the 52-week high and 52-week low respectively. Overall, CADL moved 89.46% over the past month.
Candel Therapeutics Inc’s market cap currently stands at around $407.84 million, with investors looking forward to this quarter’s earnings report slated for in January.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CADL is a 100% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend CADL as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CADL’s current price about 39.19% and 62.07% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.67, while 7-day volatility ratio is 22.57% and 22.00% in the 30-day chart. Further, Candel Therapeutics Inc (CADL) has a beta value of -1.01, and an average true range (ATR) of 1.41.
If we refocus on Candel Therapeutics Inc (NASDAQ:CADL), historical trading data shows that trading volumes averaged 18.73 over the past 10 days and 3.25 million over the past 3 months. The company’s latest data on shares outstanding shows there are 32.13 million shares.
The 41.04% of Candel Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 16.07% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.78 million on 2024-10-31, giving us a short ratio of 7.72. The data shows that as of 2024-10-31 short interest in Candel Therapeutics Inc (CADL) stood at 806.0 of shares outstanding, with shares short rising to 1.59 million registered in 2024-09-30. Current price change has pushed the stock 523.81% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CADL stock continues to rise going into the next quarter.
